secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001140361-25-038166
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris gets Danish clearance to start DurAVR THV global pivotal trial
----------------------------------------------------------------------

- Danish Medicines Agency clears Anteris to initiate DurAVR THV PARADIGM Trial for severe calcific aortic stenosis.
- Patient recruitment at Danish centers expected in 4Q 2025; trial to enroll ~1000 patients, 1:1 vs. commercial TAVR.
- IDE under FDA review; U.S. approval expected soon to allow U.S. sites in the trial.
- Study co-chairs Dr. Michael Reardon and Prof. Stephan Windecker; CMO Chris Meduri cites potential to transform care.
- Company calls approval a watershed moment, beginning commercialization planning for PMA and CE Mark.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125038166/0001140361-25-038166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125038166/ef20056802_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-038166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer